| 102.69 1.63 (1.61%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 127.97 | 1-year : | 149.47 |
| Resists | First : | 109.56 | Second : | 127.97 |
| Pivot price | 104.3 |
|||
| Supports | First : | 94.31  |
Second : | 84.87 |
| MAs | MA(5) : | 102.53 |
MA(20) : | 103.34 |
| MA(100) : | 77.8 |
MA(250) : | 69.69 |
|
| MACD | MACD : | 3.5 |
Signal : | 4.7 |
| %K %D | K(14,3) : | 18.2 |
D(3) : | 24.5 |
| RSI | RSI(14): 61.7 |
|||
| 52-week | High : | 109.56 | Low : | 47.31 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ HAE ] has closed above bottom band by 33.4%. Bollinger Bands are 31.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 102.92 - 103.41 | 103.41 - 103.85 |
| Low: | 99.37 - 99.94 | 99.94 - 100.44 |
| Close: | 101.82 - 102.72 | 102.72 - 103.5 |
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Fri, 11 Sep 2026
Haemonetics (HAE) Stock Dropped, So What Is Driving Attention Now? - simplywall.st
Tue, 08 Sep 2026
Discipline and Rules-Based Execution in HAE Response - Stock Traders Daily
Tue, 08 Sep 2026
Q1 2027 Haemonetics Corp Earnings Call Transcript - GuruFocus
Fri, 21 Aug 2026
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model (NYSE:HAE) - Seeking Alpha
Wed, 19 Aug 2026
Haemonetics Stock Jumped 16% on a CSL Plasma Deal Yesterday. Here’s What Investors Need to Know. - TIKR.com
Tue, 18 Aug 2026
Haemonetics rises after supply deal with CSL - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 46 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 112.5 (%) |
| Shares Short | 2,760 (K) |
| Shares Short P.Month | 2,700 (K) |
| EPS | 2.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.4 |
| Profit Margin | 7.1 % |
| Operating Margin | 17.9 % |
| Return on Assets (ttm) | 6.5 % |
| Return on Equity (ttm) | 11.1 % |
| Qtrly Rev. Growth | 5.5 % |
| Gross Profit (p.s.) | 17.62 |
| Sales Per Share | 29.67 |
| EBITDA (p.s.) | 7.88 |
| Qtrly Earnings Growth | 2.9 % |
| Operating Cash Flow | 328 (M) |
| Levered Free Cash Flow | 313 (M) |
| PE Ratio | 49.6 |
| PEG Ratio | 1.6 |
| Price to Book value | 5.57 |
| Price to Sales | 3.46 |
| Price to Cash Flow | 14.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|